CONTENTS

Issue 95 | June 2020

In association with

covid-19

Gilead’s remdesivir has emerged as a promising early hope for treating Covid-19

regulation

Are over-the-counter painkillers as safe as they were once thought to be?

the model body

Could modelling the body be a game-changer for drug testing?

Regulation

Consumer protection agencies are watching out for exploitative price gouging 

Pricing

Who foots the bill for new drugs and vaccines developed during a pandemic?

innovation

A new approach could help address key issues with current anticoagulants

HIV

Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill

Anti-trust

Veeva vs IQVIA: whats behind the anti-competitive data lawsuit?

research

Could nanoparticles unlock the pharmaceutical benefits of turmeric?

Comment

Why aren’t more companies automating pharmacovigilance data capture?

IMDP

Turning attention towards patient benefits with IDMP data standards implementation

05/27/2020 09:03:23
  • Home | A cure for a cost
  • In this issue
  • SHL Group Company Insight
  • Scandinavian Health
  • Contents
  • News
  • NSF
  • VEGA Company Insight
  • VEGA Australia
  • Covid-19 executive briefing by GlobalData
  • The value of real-world evidence during the Covid-19 outbreak
  • Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industry
  • Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concerns
  • AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19
  • Phoenix
  • Phoenix Company Insight
  • The pharma industry briefing
  • No time to waste: repurposing drugs to tackle covid-19
  • How safe are simple painkillers?
  • Molnar Company Insight
  • Molnar-Institute
  • Modelling the human body: a game changer for drug testing?
  • Pandemic pricing: existing drugs and price gouging
  • Contract Pharmaceuticals Limited Canada
  • Pandemic pricing: novel treatments and vaccines
  • The dark side of anticoagulants: will a new approach shed light?
  • Zenatek
  • Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill
  • Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issue
  • Nelson Labs
  • Could nanoparticles unlock the pharmaceutical benefits of turmeric?
  • Why aren’t more companies automating PV data capture?
  • Modality Solutions
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Butterworth
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Mimotopes
  • Events
  • Next issue